Beyond doubt, the interest in Active Surveillance for prostate cancer (AS, also called Expectant Management) is on the rise. A number of converging factors are driving the increase: Better early detection and diagnosis of low-risk disease Emerging science on which cell lines are unlikely to progress into lethal disease Broader awareness of the risks of keep reading

“One of my pet peeves is over-reliance on science and technology at the expense of a caring doctor-patient relationship.” Abraham Verghese, MD[i] Dr. Abraham Verghese holds a prominent place among my medical heroes because of the way he champions the doctor-patient relationship. Today, medicine seems to be dominated by devices, tests, procedures, reports, records, and economics. keep reading

It’s been three years since the US Preventive Services Task Force issued a recommendation against routine PSA screening for prostate cancer in otherwise healthy men or men who were not at known risk for the disease. It was controversial then—and not much has changed. A multi-institution team published a research letter in the Journal of keep reading

The CaPSURE registry (Cancer of the Prostate Strategic Urologic Research Endeavor) is a remarkable ongoing collection of information about prostate cancer patients drawn from 36 clinical sites that participate in this endeavor. Currently, data on more than 13,000 men exists in CaPSURE. While their identities are protected, information on factors such as date of diagnosis, keep reading

Prostatitis is an inflammation of the prostate gland that affects as many as 50% of men at some point during their lives. It is not a life threatening condition, but chronic prostatitis can make life miserable. The four main symptoms are pain, difficulty urinating, sexual dysfunction, and general health concerns such as fatigue, flu-like feelings, keep reading